Gene signature-guided dasatinib therapy in metastatic breast cancer

Clinical Cancer Research

Volumn 20, Issue 20, 2014, Pages 5265-5271

  Pusztai, Lajos ^a   Moulder, Stacy ^b   Altan, Mehmet ^a   Kwiatkowski, Danielle ^b   Valero, Vicente ^b   Ueno, Naoto T ^b   Esteva, Francisco J ^c   Avritscher, Rony ^b   Qi, Yuan ^b   Strauss, Lewis ^b   Hortobagyi, Gabriel N ^b   Hatzis, Christos ^a   Symmans, W Fraser ^d  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTOME;

ADULT; AGED; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; ER GENE; FATIGUE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE; GENE EXPRESSION PROFILING; GENETIC MARKER; HEADACHE; HEMATOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER BIOPSY; MONOTHERAPY; NAUSEA; NEUTROPENIA; ONCOGENE NEU; ONCOGENE SRC; PAIN; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PR GENE; PREDICTIVE VALUE; TUMOR BIOPSY; BIOPSY; BREAST NEOPLASMS; CLINICAL TRIAL; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY; BREAST NEOPLASMS; DASATINIB; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RISK FACTORS; SRC-FAMILY KINASES; THIAZOLES; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84909633697     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0800     Document Type: Article

References (23)

1. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-6.
2. Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011;17:5546-52.
3. Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006;13 Suppl 1:S53-9.
4. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010;16:3526-32.
5. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011;22:2234-40.
6. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011;17: 6905-13.
7. Mayer EL, Baurain J, Sparano J, Strauss L, Campone M, Fumoleau P, et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011;17:6897-904.
8. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38.
9. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
10. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, et al. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 2010;9: 1120-7.
11. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, et al. Total RNA yield and microarray gene expression profiles from fine needle aspiration and core needle biopsy samples of breast cancer. Cancer 2003;97:2960-71.
12. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 2007;13:6080-6.
13. Sotiriou C, Pusztai L. Gene expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
14. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2012;9:58-64.
15. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010;11: 358-65.
16. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010;16:711-8.
17. Kreso A, O'Brian CA, Van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013;399:543-8.
18. Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-33.
19. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006;17:813-7.
20. Johnston SRD, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-9
21. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013;93: 252-9.
22. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4: 127ps10.
23. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366-75.